Showing 1381-1390 of 1491 results for "".
- Galderma's New Face for Change Program Supports Dress for Success, Skin Cancer Foundationhttps://practicaldermatology.com/news/galdermas-new-face-for-change-program-supports-dress-for-success-skin-cancer-foundation/2460668/Galderma is launching Face for Change, a program in partnership with Dress for Success and The Skin Cancer Foundation that will allow Dysport users to give back with each treatment. Starting January 19, 2021 and ending February 28, 2021, Galderma will contribute $100
- MELA Sciences Changing Name to STRATA Skin Sciences to Reflect Broader Dermatology Commitmenthttps://practicaldermatology.com/news/mela-sciences-changing-name-to-strata-skin-sciences-to-reflect-broader-dermatology-commitment/2458771/MELA Sciences, Inc. will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and it will trade under the symbol “SSKN” on the Nasdaq Stock Market. Michael R. Stewart, President and Chief Executive Officer stated: “Our June 2015
- Vacation Tanning Linked to Acute Changes in Skin Microbiomehttps://practicaldermatology.com/news/vacation-tanning-linked-to-acute-changes-in-skin-microbiome/2461912/Sun-seeking behaviors while on vacation may affect the skin’s microbiome, new research suggests. Prior to vacations to sunny destinations, which lasted at least seven days, the researchers analyzed participants’ skin. On day one, 28, and 84 post-holiday, participants’
- Floodwaters and Climate Change Increase Risks for Dermatologic Diseasehttps://practicaldermatology.com/news/floodwaters-and-climate-change-increase-risks-for-dermatologic-disease/2459879/As more frequent and intense flooding disasters have occurred in conjunction with progressively rising temperatures, both disaster victims and relief workers have experienced significant dermatologic problems, according to
- Dermatologists Call for Changes to Off-label Coverage Decisionshttps://practicaldermatology.com/news/dermatologists-call-for-changes-to-off-label-coverage-decisions/2459926/Dermatologists report major inconsistencies in Medicare Reimbursement Policy for off-label prescriptions and are now calling for an appeal process for cases where coverage is denied. Researchers from several institutions, including the Perelman School of Medicine at the University of Pennsylvania
- Dermatologists Prescribe the Most Antibiotics, But Usage Is Changinghttps://practicaldermatology.com/news/dermatologists-prescribe-the-most-antibiotics-but-usage-is-changing/2459935/The use of antibiotics to treat inflammatory skin conditions like acne and rosacea is decreasing over time, but there has been an increase in prescriptions associated with dermatologic surgical procedures, a new study finds. The study appears in
- Intraderm Changes Alevicyn Product Name to Levicynhttps://practicaldermatology.com/news/intraderm-changes-alevicyn-product-name-to-levicyn/2457910/Intraderm's Alevicyn is getting a new name—Levicyn. The Gel formulation is now Levicyn Antipruritic Gel, the Spray Gel is now Levicyn Antipruritic SG, and the Dermal Spray is now Levicyn Antimicrobial Dermal Spray. The company notes that physicians can still write for Alevicyn d
- Crescita Therapeutics Announces Management and Board Changeshttps://practicaldermatology.com/news/crescita-therapeutics-announces-management-and-board-changes/2458293/Crescita Therapeutics Inc., a commercial dermatology company with a portfolio of over-the-counter and prescription products for the treatment and care of skin diseases and their symptoms, introduced Ms. Muneerah Kanji, MBA, CPA, CA, Crescita's Corporate Controll
- Provectus Announces Name Change to Provectus Biopharmaceuticalshttps://practicaldermatology.com/news/20131218-provectus_announces_name_change_to_provectus_biopharmaceuticals/2459391/
- New Baricitinib AA Data for Adolescents Could Be 'Game-Changing'https://practicaldermatology.com/news/New-Baricitinib-AA-Data-Adolescents-Could-Be-Game-Changing/2471600/Patients ages 12 to under 18 with severe alopecia areata (AA) treated with once-daily, oral baricitinib 4 mg and 2 mg saw clinically meaningful improvements in hair regrowth on the scalp, eyebrows, and eyelashes at Week 36 in the Phase 3 BRAVE-AA-PEDS study, presented as a late-breaker at the 202